相关实验视频

Updated: Mar 10, 2026

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Published on: October 10, 2017

用甲胺加载的J-AuPPS用于感染糖尿病的伤口治疗

Fuli Yin¹, Lingkai Yang¹, Haojie Shan¹

¹Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in bioengineering and biotechnology

|March 9, 2026

概括

一种新的Janus金氨酸聚合体异构结构,加载了甲胺 (Met@J-AuPPS),可以有效地治疗受感染的糖尿病伤口. 这种纳米材料显示出出色的抗菌,抗菌膜和益血管性质,在糖尿病老鼠模型中增强伤口愈合.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
伤口愈合治愈伤口愈合

背景情况:

糖尿病伤口由于其微观环境而带来复杂的挑战.
多功能纳米材料为感染的糖尿病伤口提供了协同治疗方法.

研究的目的:

构建并呈现一个装有甲胺 (Met@J-AuPPS) 的Janus金-氨酸聚合体异构结构.
评估Met@J-AuPPS在治疗感染糖尿病伤口中的疗效.

主要方法:

通过超分子聚合和光催化方法合成甲胺载的氨酸聚合体囊泡 (Met@PPS) 和Met@J-AuPPS.
使用TEM,SEM,UV-vis和ELISA进行表征.
在体外评估HUVEC的扩散,活性,抗菌和抗菌膜能力.
在糖尿病老鼠伤口模型中使用成像和组织学分析进行体内疗效评估.

主要成果:

由于近场增强,Met@J-AuPPS证明了对MRSA和ESBL大肠杆菌 (包括生物膜) 的优良光热抗菌活性.
通过NIR光触发的甲福明释放促进了血管新生和组织修复.
在感染糖尿病的老鼠伤口模型中观察到显著的治疗效果.

结论:

Met@J-AuPPS表现出强大的抗菌/生物膜和益血管性能的性能.
这项研究提出了糖尿病伤口感染的创新治疗策略.
Met@J-AuPPS显示了作为生物医学应用的多功能纳米平台的潜力.

关键词:

亚努斯粒子亚努斯粒子血管新生的产生.它是一种抗菌药物,具有抗菌作用.糖尿病的伤口感染.光热疗法是一种光热疗法.协同效应疗法是一种协同效应疗法.

更多相关视频

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...